Mednax (MD) Earning Somewhat Favorable Press Coverage, Report Shows

Media coverage about Mednax (NYSE:MD) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mednax earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.4859200482949 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Mednax (NYSE MD) traded down $0.18 on Friday, hitting $44.47. The stock had a trading volume of 1,652,900 shares, compared to its average volume of 1,005,275. The company has a market cap of $4,181.71, a price-to-earnings ratio of 13.65, a PEG ratio of 1.44 and a beta of 0.32. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. Mednax has a 1-year low of $40.56 and a 1-year high of $72.13.

Mednax (NYSE:MD) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, hitting the consensus estimate of $0.87. The business had revenue of $868.95 million during the quarter, compared to analyst estimates of $864.78 million. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The company’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $1.09 EPS. equities research analysts expect that Mednax will post 3.1 EPS for the current fiscal year.

MD has been the topic of several research analyst reports. Robert W. Baird reiterated a “hold” rating and set a $47.00 price target on shares of Mednax in a research report on Sunday, September 3rd. BidaskClub cut Mednax from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. KeyCorp upgraded Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price target on the stock in a research report on Sunday, September 17th. BMO Capital Markets initiated coverage on Mednax in a research report on Monday, October 16th. They set a “market perform” rating and a $46.00 price target on the stock. Finally, Zacks Investment Research upgraded Mednax from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the stock. Mednax has an average rating of “Hold” and an average price target of $54.50.

TRADEMARK VIOLATION NOTICE: “Mednax (MD) Earning Somewhat Favorable Press Coverage, Report Shows” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/11/mednax-md-receives-daily-coverage-optimism-score-of-0-17.html.

In other news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply